Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
about
DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activationCD40 immunotherapy for pancreatic cancerToll-like receptor 9, transmembrane activator and calcium-modulating cyclophilin ligand interactor, and CD40 synergize in causing B-cell activation.Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trialSerial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters.Toll-like receptor 9 polymorphisms influence mother-to-child transmission of human immunodeficiency virus type 1.Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors.Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population.Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates.CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome.Toll-like receptor 9 agonists as cancer therapeutics.Potential impact of B cells on T cell function in multiple sclerosisTargeting costimulatory molecules to improve antitumor immunity.The use of agonistic anti-CD40 therapy in treatments for cancer.T-cell-independent antitumor effects of CD40 ligation.Immune dysfunction in cirrhosis.Cytosine-phosphate-guanosine-DNA induces CD274 expression in human B cells and suppresses T helper type 2 cytokine production in pollen antigen-stimulated CD4-positive cells.The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities.Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity.In vitro and in vivo imaging of initial B-T-cell interactions in the setting of B-cell based cancer immunotherapy.A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.A safety study of a B-class CpG ODN in Sprague-Dawley rats.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Echinococcus granulosus glycoconjugates induce peritoneal B cell differentiation into antibody-secreting cells and cytokine production.The Use of Anti-CD40 mAb in Cancer.Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
P2860
Q24321675-52ED8F08-676E-4DD2-A660-10A3A4EBD5E0Q27012550-F400E671-7BDA-4777-9E96-3189C8FB9A9EQ30425171-ACF74681-EF6D-475E-90C8-8F69FC1A4746Q33557015-3CD14E6D-F08E-4E3F-852C-B26A9C940AB0Q33805073-06F83E08-D770-4982-8621-3E622D59F1B5Q33920072-B0B1993B-4EFE-4C95-931B-32D5B685C0EBQ34616576-46FAC076-14B1-4206-A83D-39F46A6B7984Q35633193-91FDDCE2-315F-40E9-B403-C93159A2AED1Q35864569-54B30ABF-7FDD-4CEE-ADB0-C2892A00276FQ36002320-53085F4F-19BE-4233-95C2-705C5326142DQ37831323-037681F1-635D-491A-A72C-1D81A023C023Q37957892-1E6FDA4D-DC3F-4769-8AA1-FA1A6C15E499Q38002404-13EC5540-1F5D-4011-816C-D498AA835653Q38026924-9EC5F044-D123-4D57-8D16-F05E079D387DQ38026925-36585209-5393-46B7-8D13-A0C2554A19FDQ38195835-07E03E6F-22C2-4C2D-A7F8-88EA35B6203AQ38324724-7160EF77-6407-42BB-AC8A-5C5EC4B853DAQ39172481-E242442A-C1AF-4AB1-B79C-BDCD8C76D829Q39381907-F2DC20FB-D4CE-44D2-980C-2496990BA96DQ40502860-F17ECF96-1FA3-4646-B03E-7A4ACF24B9EFQ40522944-BFC7F803-2E77-43C6-9D49-BA0E5B61A678Q41855863-8F88B899-EDFA-45E4-8060-6E7BE06329E3Q44349028-3B159E18-46AE-4DE7-9956-FBE441AED2CBQ47325431-193DDAE4-F899-4531-AFFA-F347B5FDCAAFQ53089941-64136A75-A641-41AC-AF6E-F3E15FE06764Q53321210-E3A47572-6223-4538-B553-803A6F1EAEA2Q57132855-22C57F52-11E6-4A6D-AF88-2062A3C961A6
P2860
Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Activation of human B cells by ...... l-like receptor 9 stimulation.
@en
Activation of human B cells by ...... l-like receptor 9 stimulation.
@nl
type
label
Activation of human B cells by ...... l-like receptor 9 stimulation.
@en
Activation of human B cells by ...... l-like receptor 9 stimulation.
@nl
prefLabel
Activation of human B cells by ...... l-like receptor 9 stimulation.
@en
Activation of human B cells by ...... l-like receptor 9 stimulation.
@nl
P2093
P2860
P356
P1476
Activation of human B cells by ...... l-like receptor 9 stimulation.
@en
P2093
Erica L Carpenter
Jens Rüter
Robert H Vonderheide
Rosemarie Mick
P2860
P2888
P356
10.1186/1479-5876-7-93
P577
2009-11-11T00:00:00Z
P5875
P6179
1035902284